Cen Junda (#530)
- $ 7 B
- Pharmaceuticals
- China
- M
- 61 Years
'A form of double taxation': Are management fees on new houses quietly getting out of control?
Trump Official Blames Biden Admin for Economic ‘Mess’ — As Resurfaced Clip Shows Him Saying Trump Would Own the Economy By 2026
Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?
Is Transocean Ltd. (RIG) A Good Stock To Buy Now?
Tesla is selling Chinese-made cars in Canada to escape the tariffs that both China and America imposed on it
Insecurity didn’t start with Tinubu, group defends president’s security record
Vibrating pillow sleeve warns deaf sleepers of burglars and fires
How Kepler built verifiable AI for financial services with Claude
Is ASML Holding N.V. (ASML) A Good Stock To Buy Now?
5-Letter Words Ending in ‘Y’ to Help You Improve Your Wordle Skills
About Me
Cen Junda's fortune stems from his stakes in Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group. China-based Hansoh operates a research center in the U.S. state of Maryland. He holds degrees from Zhejiang University and the China State Institute of Pharmaceutical Industry.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Cen Junda’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Cen Junda’s net worth journey over the years, highlighting key growth phases and financial milestones.
Current Net Worth: $7.3B
(May 4, 2026)
© Iconic Billionaires